Circulating Tumor Cells Market Players: BIOCEPT, Inc., Biocep Ltd., Ikonisys Inc., And Miltenyi Biotec

 Circulating Tumor Cells Industry Overview

The global circulating tumor cells market size is expected to reach USD 18.3 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.7% from 2021 to 2027. Many potential applications of CTCs in pre-diagnosis, pretreatment, and intra- and post-treatment provide lucrative growth opportunities to players involved in the development of CTC enrichment and isolation products Research organizations are engaged in endeavors aimed at developing CTC-based tests to improve cancer diagnosis in terms of efficiency and speed.

 

Furthermore, the growing demand for minimally invasive diagnostic procedures is anticipated to propel investments by key stakeholders in this area. CTC-based liquid biopsy tests lead to limited trauma and enable rapid recovery owing to their non-invasive nature. Moreover, it enables minimal invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors, thus positively impacting the adoption.

The limited applicability of these cells in rare cancers has hampered the revenue growth up to a certain extent. For instance, there is negligible evidence for the characterization of CTCs for sarcoma. Conversely, several methods are being investigated for the isolation of these cells, such as methods based on epithelial antigen-targeted antibodies, which are anticipated to help overcome these challenges in the coming years.


Circulating Tumor Cells Market Segmentation

Grand View Research has segmented the global Circulating Tumor Cells market on the basis of technology, application, product, specimen, and region:

Based on the Technology Insights, the market is segmented into CTC Detection & Enrichment Methods, CTC Direct Detection Methods, and CTC Analysis.

  • The CTC detection and enrichment methods segment accounted for the largest revenue share of 65.8%. The availability of different methods for the enrichment of circulating tumor cells in cancer detection is expected to significantly impact segment growth over the forecast period.

 

  • Advancements in technologies such as immunofluorescence, NGS, FISH, and qPCR are anticipated to drive the clinical utility of these cells, and thus accelerating revenue growth for CTC analyses. Several companies are investing in the development of products that help in CTC analysis and downstream assays. For instance, Vortex Biosciences offers various CTC analysis products, including immunofluorescence, cytopathology, cytogenetics (FISH), cell culture, and genomics.

 

Based on the Application Insights, the market is segmented into Clinical/ Liquid Biopsy, and Research.

  • The research segment dominated the market and captured the largest revenue share of 72.8% in 2020. Circulating tumor cells are regarded as a substrate of cancer metastasis. Circulating tumor cells enumeration remains largely a research tool.

 

  • This arena has significantly improved cancer studies, thus, products offered in the market are primarily designed to be used within research settings. Some key products that have contributed to the large share of research settings are Parsortix Technology, Target Selector Platform, Apostream, Celsee PREP 400, IsoFlux CTC system, DEPArray System, VTX-1, and AdnaTest.

 

Based on the Product Insights, the market is segmented into Kits & Reagents, Blood Collection Tubes, and Devices or Systems.

  • The devices or systems segment dominated the market and accounted for the largest revenue share of 42.8% in 2020. This can be attributed to the presence of a wide portfolio under this category coupled with upcoming advances with regard to microfluidics technology.

 

  • The development of automated instruments that eliminates the use of additional blood collection tubes hampers the revenue growth of blood collection tubes. The reduction in costs is also observed as the transportation is free of the additional laboratory consumables and transfer tubes when the reagent-equipped tubes are used.

 

Based on the Specimen Insights, the market is segmented into Blood, Bone Marrow, and Other Body Fluids.

  • The blood specimen segment dominated the market and accounted for the largest revenue share of 46.9% in 2020. A large concentration of these cells in blood samples as compared with other biospecimens is responsible for the largest penetration of this specimen type.

 

  • Membrane clogging as a result of a high concentration of blood cells minimizes the applicability of whole blood samples in microfluidic-based circulating tumor cells enumeration. Devices with various pore shapes and sizes are anticipated to overcome this issue and drive segment growth in the coming years.

 

CTCs Regional Outlook

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

The market is consolidated with several emerging as well as established players. The market is witnessing high competition among both public and private firms. The players are adopting several measures to sustain market competition with the changing trends which exerts a positive impact on the overall market. The companies are collaborating with other market players to gain a competitive advantage in the space.

For instance, in November 2019, Biolidics Limited signed an agreement with Sysmex Corporation to develop a laboratory-developed test for the diagnosis of cancer. Since 2016, the companies collaborated for R&D of laboratory assays in this field by using ClearCell FX1 System along with Sysmex’s MI-FCM, a molecular imaging flow cytometer. This extension in collaboration helped the company expand its product portfolio. Some of the prominent players in the Circulating Tumor Cells (CTCs) market include:

  • QIAGEN
  • Bio-Techne Corporation
  • Precision for Medicine
  • AVIVA Biosciences
  • BIOCEPT, Inc.
  • BioCEP Ltd.
  • Fluxion Biosciences, Inc.
  • Greiner Bio One International GmbH
  • Ikonisys Inc.
  • Miltenyi Biotec
  • IVDiagnostics
  • BioFluidica
  • Canopus Bioscience Ltd.
  • Biolidics Limited
  • Creativ MicroTech, Inc.
  • LungLife AI, Inc.
  • Epic Sciences
  • Rarecells Diagnostics
  • ScreenCell
  • Menarini Silicon Biosystems
  • LineaRx, Inc. (Vitatex, Inc.)
  • Sysmex Corporation
  • STEMCELL Technologies, Inc.

 

Order a free sample PDF of the CTCs Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

 

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

Follow Us: LinkedIn | Twitter

Comments

Post a Comment

Popular posts from this blog

Dna-Based Skin Care Products Market: Offline Distribution Channel Led And Held A Revenue Share

  DNA-based Skin Care Products Industry Overview The global  DNA-based skin care products market  size is expected to reach USD 9.87 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.6% from 2021 to 2028. Consumer awareness of the dangers of using skincare products containing synthetic chemicals is pushing the demand for natural and organic products. Many DNA-based companies have been promoting awareness of DNA-based skincare products through digital and social media campaigns because today's consumers are tech-savvy and want products that are best suited to them.   Everyone's skin is different, so instead of a generic approach from over-the-counter items, consumers need a regimen that is tailored to their own needs. Consumers are now being targeted more directly by skincare specialists, who are prescribing a customized range of products. The Skin360 Face Scanner app from Neutrogena identifies over two...
Read more

Flow Cytometry Market: Asia Pacific Is Projected To Exhibit Exponential Growth During The Forecast Period

  Flow Cytometry Industry Overview The global  flow cytometry market  size is expected to reach a value of USD 11.5 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.9% from 2021 to 2027. The high prevalence of chronic diseases, the introduction of technologically advanced flow cytometry solutions, and increasing R&D investments in the pharmaceutical industry are expected to propel market growth over the forecast period.   Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. Also, in January 2019, Beckman Coulter, a subsidiary of Danaher Corporation, expanded its clinical flow cytometry portfolio with the launch of its new ClearLLab 10C System. This newly la...
Read more